<DOC>
	<DOC>NCT02933658</DOC>
	<brief_summary>A non-randomized, two-arm, single-sequence, crossover, open label, multiple oral dosing clinical trial to evaluate the safety and the pharmacokinetic drug-drug interaction of Telmisartan/Amlodipine and Rosuvastatin in healthy male volunteers</brief_summary>
	<brief_title>Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy male who are â‰¥19, &lt;50 years old Man who weights over 55kg and whose BMI is 18~30(kg/m2) Man who doesn't have any chronic disease or history of disease man who has or had any clinically relevant disease of liver, kidney, nervous/respiratory/musculoskeletal/cardiovascular/hematooncology system or neuropsychiatry</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>